Meeting Oligo System Development Challenges Head-On
By Steve Foy, Product Marketing Manager, Asahi Kasei Bioprocess America
Asahi Kasei Bioprocess America (AKBA) is devoted to solving therapeutic product safety, efficiency and purity challenges within the pharmaceutical and bioprocessing industries.
By focusing our expertise on fluid management technology, our portfolio of market-driven equipment and cutting-edge technology touches unit operations across a wide range of therapeutic modalities, including classical small molecule pharmaceuticals, current-generation antibodies, plasma derivatives and next-generation oligonucleotide therapeutics.
The GEMÜ Group is a family-owned, leading manufacturer of valves, measurement and control systems for liquids, vapors and gases – as well as a global market leader in sterile application solutions.
Read more how this partnership is redefining what is possible in oligonucleotide manufacturing.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.